Developing strategies to minimize the impact of extended-spectrum β-lactamases: Focus on cefepime

Clinical Infectious Diseases

Volumn 42, Issue SUPPL. 4, 2006, Pages

  Ramphal, Reuben ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM IDENTIFICATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG USE; EDITORIAL; ENTEROBACTER; ENZYME ACTIVITY; ENZYME SYNTHESIS; ESCHERICHIA COLI; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; PLASMID; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST;

EID: 33645794760     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/500661     Document Type: Editorial

References (3)

1. Pfaller MA, Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum β-lactamases. Clin Infect Dis 2006; 42(Suppl 4):S153-63 (in this supplement).
2. Ramphal R, Ambrose PG. Extended-spectrum β-lactamases and clinical outcomes: current data. Clin Infect Dis 2006; 42(Suppl 4):S164-72 (in this supplement).
3. Owens RC Jr, Rice L. Hospital-based strategies for combating resistance. Clin Infect Dis 2006; 42(Suppl 4):S173-81 (in this supplement).